NEW YORK (GenomeWeb News) — 23andMe and Swiss company Mondobiotech will collaborate to offer researchers information about certain rare genetic diseases, the California consumer genomics firm said today.
The collaboration will use genetic information from individuals who suffer from diseases such as pulmonary arterial hypertension, sarcoidoisis, and pulmonary fibrosis. Mondobiotech will identify these patients and sponsor their enrollment in 23andMe's Personal Genome Service.
23andMe said that it will coordinate genome-wide association studies for Mondobiotech affiliates using its research infrastructure and bioinformatics expertise.
Mondobiotech CEO Fabio Cavalli said in a statement that this collaboration "could go a long way towards understanding the causes of the diseases we have been researching."
Financial terms of the agreement were not released.